SARS-CoV-2

University of Cambridge researchers suggest that exposure to SARS-CoV-2 may limit the immune system's ability to respond to future coronavirus variants. They emphasize the importance of vaccine boosters in maintaining effective immunity against evolving strains.

Researchers in the United Kingdom successfully tested the world's first AI-designed vaccine in humans, which targets a broad range of coronaviruses, including potential future strains. The vaccine demonstrated safety and immune responses against SARS-CoV-2 and related viruses, though further studies are required to confirm its efficacy.

An AI-designed 'universal vaccine' targeting multiple coronaviruses has passed its first human clinical trial, showing safety and triggering an immune response in 39 volunteers. Developed by researchers from the Universities of Cambridge and Southampton, the vaccine uses a computer-simulated 'super-antigen' to combat evolving viruses, including those not yet discovered. The needle-free micro-fluid jet delivery method aims to simplify mass administration.

Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it safe and well-tolerated. The vaccine generated immune responses against multiple coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential.

A study found 54 distinct viruses in dust from buildings, including SARS-CoV-2, influenza, and norovirus. The discovery highlights the presence of potentially harmful pathogens in office environments. The research suggests that dust can be a reservoir for viruses.

Researchers discovered compounds called galloylquinic acids from a Brazilian tree that can attack SARS-CoV-2 in multiple ways, blocking its entry into cells and disrupting replication. These natural compounds have potential to make it harder for resistance to develop. The discovery may lead to new treatments against COVID-19.